



- (51) **International Patent Classification:**  
*A61K 31/538* (2006.01) *A61P 31/04* (2006.01)
- (21) **International Application Number:**  
PCT/IB2015/001585
- (22) **International Filing Date:**  
27 May 2015 (27.05.2015)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**  
62/004,246 29 May 2014 (29.05.2014) US
- (71) **Applicant:** ENTASIS THERAPEUTICS LIMITED  
[GB/GB]; 2 Kingdom Street, London W2 6BD (GB).
- (72) **Inventor:** HUBAND, Michael; Astrazeneca R&d Boston,  
35 Gatehouse Drive, Waltham, MA 02451 (US).
- (74) **Agent:** STEVENS, Ian E.; Potter Clarkson LLP, The Bel-  
grave Centre, Talbot Street, Nottingham NG1 5GG (GB).
- (81) **Designated States** (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,  
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,

DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,  
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,  
KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,  
MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,  
PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,  
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,  
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

- (84) **Designated States** (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,  
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,  
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,  
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,  
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,  
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,  
GW, KM, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments (Rule 48.2(h))



WO 2015/181637 A1

(54) **Title:** FUSED, SPIROCYCLIC HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS

(57) **Abstract:** Disclosed are methods for treating various bacterial infections with (2*R*,4*S*,4*aS*)-11-fluoro-2,4-dimethyl-8-[(4*S*)-4-methyl-2-oxo-1,3-oxazolidin-3-yl]-1,2,4,4a-tetrahydro-2'*H*,6'*H*-spiro[1,4-oxazino[4,3-*a*][1,2]oxazolo[4,5-*g*]quinoline-5,5'-pyrimidine]-2',4',6' (1'*H*,3'*H*)-trione, or a pharmaceutically acceptable salt thereof.

## FUSED, SPIROCYCLIC HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS

### Background

Antibiotic tolerance and resistance has become a grave threat to the successful  
5 treatment of many common bacterial infections. Indeed, according to the Infectious Disease Society of America, methicillin resistant *Staphylococcus aureus* (MRSA) kills more Americans every year than emphysema, HIV/AIDS, Parkinson's disease and homicide combined. Not only is multi-drug resistance in common infectious Gram-positive and  
-negative pathogens such as *Enterococcus faecium*, *Staphylococcus aureus*, *Klebsiella*  
10 *pneumoniae*, *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, *Mycobacterium tuberculosis* and *Enterobacter* species on the rise, but evidence of resistance is being seen in *Salmonella* and *Clostridium difficile*, and increasingly *Neisseria gonorrhoeae* (Gerard D. Wright, "Antibiotics: A New Hope," 19 (2012), 3-10). Due to this increase in resistance, the development of new antibacterial medicines is an important medical need.

15

### Summary

There remains a need for new therapies for treating bacterial infections. There is provided the compound (2*R*,4*S*,4*aS*)-11-fluoro-2,4-dimethyl-8-[(4*S*)-4-methyl-2-oxo-1,3-oxazolidin-3-yl]-1,2,4,4*a*-tetrahydro-2'*H*,6'*H*-spiro[1,4-oxazino[4,3-*a*][1,2]oxazolo[4,5-  
20 *g*]quinoline-5,5'-pyrimidine]-2',4',6'-(1'*H*,3'*H*)-trione, or a pharmaceutically acceptable salt thereof, for potential use for treating bacterial infections.

In one aspect, there is provided a method for treating a bacterial infection caused by *Bacillus anthracis*, *Bacillus cereus*, *Burkholderia spp.*, *Brucella spp.*, *Francisella spp.*, *Yersina spp.*, *Mycoplasma spp.*, *Ureaplasma spp.*, *Chlamydia trachomatis* or *Chlamydia*  
25 *pneumoniae* in a subject in need thereof comprising administering an effective amount of (2*R*,4*S*,4*aS*)-11-fluoro-2,4-dimethyl-8-[(4*S*)-4-methyl-2-oxo-1,3-oxazolidin-3-yl]-1,2,4,4*a*-tetrahydro-2'*H*,6'*H*-spiro[1,4-oxazino[4,3-*a*][1,2]oxazolo[4,5-*g*]quinoline-5,5'-pyrimidine]-2',4',6'-(1'*H*,3'*H*)-trione, or a pharmaceutically acceptable salt thereof, to the subject.

In one aspect, there is provided the use of (2*R*,4*S*,4*aS*)-11-fluoro-2,4-dimethyl-8-  
30 [(4*S*)-4-methyl-2-oxo-1,3-oxazolidin-3-yl]-1,2,4,4*a*-tetrahydro-2'*H*,6'*H*-spiro[1,4-oxazino[4,3-*a*][1,2]oxazolo[4,5-*g*]quinoline-5,5'-pyrimidine]-2',4',6'-(1'*H*,3'*H*)-trione, or a pharmaceutically acceptable salt thereof, for treating a bacterial infection caused by one or more bacterium selected from *Bacillus anthracis*, *Bacillus cereus*, *Burkholderia spp.*, *Brucella spp.*, *Francisella spp.*, *Yersina spp.*, *Mycoplasma spp.*, *Ureaplasma spp.*, *Chlamydia trachomatis*  
35 or *Chlamydia pneumoniae*.

In one aspect, there is provided the use of (2*R*,4*S*,4*aS*)-11-fluoro-2,4-dimethyl-8-[(4*S*)-4-methyl-2-oxo-1,3-oxazolidin-3-yl]-1,2,4,4*a*-tetrahydro-2'*H*,6'*H*-spiro[1,4-oxazino[4,3-


a)[1,2]oxazolo[4,5-g]quinoline-5,5'-pyrimidine]-2',4',6'-(1'H,3'H)-trione, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating a bacterial infection caused by one or more bacterium selected from *Bacillus anthracis*, *Bacillus cereus*, *Burkholderia* spp., *Brucella* spp., *Francisella* spp., *Yersina* spp., *Mycoplasma* spp., *Ureaplasma* spp., *Chlamydia trachomatis* or *Chlamydia pneumoniae*.

In one aspect, there is provided a pharmaceutical composition comprising (2*R*,4*S*,4*aS*)-11-fluoro-2,4-dimethyl-8-[(4*S*)-4-methyl-2-oxo-1,3-oxazolidin-3-yl]-1,2,4,4*a*-tetrahydro-2'*H*,6'*H*-spiro[1,4-oxazino[4,3-*a*][1,2]oxazolo[4,5-*g*]quinoline-5,5'-pyrimidine]-2',4',6'-(1'*H*,3'*H*)-trione, or a pharmaceutically acceptable salt thereof, for treating a bacterial infection caused by one or more bacterium selected from *Bacillus anthracis*, *Bacillus cereus*, *Burkholderia* spp., *Brucella* spp., *Francisella* spp., *Yersina* spp., *Mycoplasma* spp., *Ureaplasma* spp., *Chlamydia trachomatis* or *Chlamydia pneumoniae*.

### Detailed Description

There are provided methods of treating bacterial infections caused by one or more bacterium selected from *Bacillus anthracis*, *Bacillus cereus*, *Burkholderia* spp., *Brucella* spp., *Francisella* spp., *Yersina* spp., *Mycoplasma* spp., *Ureaplasma* spp., *Chlamydia trachomatis* or *Chlamydia pneumoniae* by administering to a subject in need thereof an effective amount of (2*R*,4*S*,4*aS*)-11-fluoro-2,4-dimethyl-8-[(4*S*)-4-methyl-2-oxo-1,3-oxazolidin-3-yl]-1,2,4,4*a*-tetrahydro-2'*H*,6'*H*-spiro[1,4-oxazino[4,3-*a*][1,2]oxazolo[4,5-*g*]quinoline-5,5'-pyrimidine]-2',4',6'-(1'*H*,3'*H*)-trione, or a pharmaceutically acceptable salt thereof.

The compound (2*R*,4*S*,4*aS*)-11-fluoro-2,4-dimethyl-8-[(4*S*)-4-methyl-2-oxo-1,3-oxazolidin-3-yl]-1,2,4,4*a*-tetrahydro-2'*H*,6'*H*-spiro[1,4-oxazino[4,3-*a*][1,2]oxazolo[4,5-*g*]quinoline-5,5'-pyrimidine]-2',4',6'-(1'*H*,3'*H*)-trione has the following structure:



The aforementioned compound, and its method of synthesis, is disclosed in International Application No. PCT/GB2014/050164, which is expressly incorporated herein in its entirety.

The language "bacterial infection" includes infections caused by one or more species of Gram-negative, Gram-positive, or atypical bacteria.

In some embodiments, the bacterial infection is caused by *Bacillus anthracis* or *Bacillus cereus*.

In some embodiments, the bacterial infection is caused by *Burkholderia* spp., for

example, *Burkholderia mallei*, *Burkholderia pseudomallei* and *Burkholderia cepacia*.

In some embodiments, the bacterial infection is caused by *Brucella spp.*, for example, *Brucella melitensis*, *Brucella abortus*, *Brucella canis*, *Brucella suis* and *Brucella ovis*.

5 In some embodiments, the bacterial infection is caused by *Francisella spp.*, for example, *Francisella tularensis*, *Francisella novicida* and *Francisella philomiragia*.

In some embodiments, the bacterial infection is caused by *Yersinia spp.*, for example, *Yersinia pestis* and *Yersinia enterocolitica*.

10 In some embodiments, the bacterial infection is caused by *Mycoplasma spp.*, for example *Mycoplasma gallisepticum*, *Mycoplasma genitalium*, *Mycoplasma haemofelis*, *Mycoplasma hominis*, *Mycoplasma hyopneumoniae*, *Mycoplasma ovipneumoniae* and *Mycoplasma pneumoniae*.

In some embodiments, the bacterial infection is caused by *Ureaplasma spp.*, for example, *Ureaplasma parvum* and *Ureaplasma urealyticum*

15 In some embodiments, the bacterial infection is caused by *Chlamydia trachomatis* or *Chlamydia pneumoniae*.

In some embodiments, the bacteria are resistant to one or more antibacterials other than (2*R*,4*S*,4*aS*)-11-fluoro-2,4-dimethyl-8-[(4*S*)-4-methyl-2-oxo-1,3-oxazolidin-3-yl]-1,2,4,4*a*-tetrahydro-2'*H*,6'*H*-spiro[1,4-oxazino[4,3-*a*][1,2]oxazolo[4,5-*g*]quinoline-5,5'-pyrimidine]-2',4',6'(1'*H*,3'*H*)-trione. The language "resistance" and "antibacterial resistance" refers to bacteria that are able to survive exposure to one or more antibacterial agents. In one embodiment, the bacteria is resistant to one or more of an aminoglycoside antibiotic (e.g., amikacin, gentamicin, kanamycin, neomycin, netilmicin, tobramycin, paromomycin, spectinomycin), an ansamycin antibiotic (e.g., rifaximin, streptomycin), a carbapenem antibiotic (e.g., ertapenem, doripenem, imipenem/cilastatin, meropenem), a cephalosporin antibiotic (e.g., cefadroxil, cefaxolin, cefatolin, cefalexin, cefaclor, cefamandole, cefoxitin, cefprozil, cefuroxime, cefisime, cefdinir, cefditoren, cefoperazone, cefotaxime, cefpodoxime, ceftazidime, certibuten, ceftizoxime, ceftriaxone, cefepime, ceftarolin fosamil, ceftobiprole), a glycopeptide antibiotic (e.g., teicoplanin, vancomycin, telavancin), a lincosamide antibiotic (e.g., clindamycin, lincomycin), daptomycin, a macrolide antibiotic (e.g., azithromycin, clarithromycin, dirithromycin, erythromycin, roxithromycin, troleandomycin, telithromycin, spiramycin), aztreonam, furazolidone, nitrofurantoin, an oxazolidinone antibiotic (e.g., linezolid, posizolid, radezolid, torezolid), a penicillin antibiotic (e.g., amoxicillin, ampicillin, azlocillin, carbenicillin, cloxacillin, dicloxacillin, flucloxacillin, mezlocillin, methicillin, nafcillin, oxacillin, penicillin, piperacillin, temocillin, ticarcillin), amoxicillin/clavulante, 25 30 35  
ampicillin/sulbactam, piperacillin/tazobactam, ticarcillin/clavulanate, a quinolone antibacterial (e.g., ciprofloxacin, enoxacin, gatifloxacin, gemifloxacin, levofloxacin, lomefloxacin,

moxifloxacin, nalidixic acid, norfloxacin, ofloxacin, trovafloxacin, grepafloxacin, sparfloxacin, temafloxacin), a sulfonamide antibiotic (e.g., mafenide, sulfacetamide, sulfadiazine, silver sulfadiazine, sulfadimethoxine, sulfamethizole, sulfamethoxazole, sulfanilimide, sulfasalazine, sulfisoxazole, trimethoprim/sulfamethoxazole - TMP-SMX) and a tetracycline antibiotic (e.g., demeclocycline, doxycycline, minocycline, oxytetracycline, tetracycline, tigecycline). In some embodiments, the bacteria is resistant to doxycycline. In some  
5  
embodiments, the bacteria is resistant to levofloxacin and/or ciprofloxacin. In some  
embodiments, the bacteria is resistant to azithromycin. In some embodiments, the bacteria  
is resistant to tetracycline.

10 In some embodiments, there is provided a method of treating a subject suffering  
from a sexually transmitted bacterial infection comprising administering to the subject an  
effective amount of a (2*R*,4*S*,4*aS*)-11-fluoro-2,4-dimethyl-8-[(4*S*)-4-methyl-2-oxo-1,3-  
oxazolidin-3-yl]-1,2,4,4*a*-tetrahydro-2'*H*,6'*H*-spiro[1,4-oxazino[4,3-*a*][1,2]oxazolo[4,5-  
g]quinoline-5,5'-pyrimidine]-2',4',6'(1'*H*,3'*H*)-trione, or a pharmaceutically acceptable salt  
15 thereof.

In some embodiments, there is provided (2*R*,4*S*,4*aS*)-11-fluoro-2,4-dimethyl-8-  
[(4*S*)-4-methyl-2-oxo-1,3-oxazolidin-3-yl]-1,2,4,4*a*-tetrahydro-2'*H*,6'*H*-spiro[1,4-oxazino[4,3-  
*a*][1,2]oxazolo[4,5-*g*]quinoline-5,5'-pyrimidine]-2',4',6'(1'*H*,3'*H*)-trione, or a pharmaceutically  
acceptable salt thereof, for use in treating a bacterial infection caused by one or more  
20 bacterium selected from *Bacillus anthracis*, *Bacillus cereus*, *Burkholderia spp.*, *Brucella spp.*,  
*Francisella spp.*, *Yersina spp.*, *Mycoplasma spp.*, *Ureaplasma spp.*, *Chlamydia trachomatis*  
or *Chlamydia pneumoniae*.

In one aspect, there is provided a method for treating an anthrax infection, glanders,  
melioidosis, a pulmonary infection in a subject suffering from cystic fibrosis, brucellosis,  
25 tularemia, plague, sepsis, yersiniosis, pelvic inflammatory disease, atypical pneumonia, non-  
specific urethritis, pneumonia, bronchopulmonary dysplasia or meningitis in a subject in  
need thereof comprising administering an effective amount of (2*R*,4*S*,4*aS*)-11-fluoro-2,4-  
dimethyl-8-[(4*S*)-4-methyl-2-oxo-1,3-oxazolidin-3-yl]-1,2,4,4*a*-tetrahydro-2'*H*,6'*H*-spiro[1,4-  
oxazino[4,3-*a*][1,2]oxazolo[4,5-*g*]quinoline-5,5'-pyrimidine]-2',4',6'(1'*H*,3'*H*)-trione, or a  
30 pharmaceutically acceptable salt thereof, to the subject.

The language "treat," "treating" and "treatment" includes the reduction or inhibition  
of enzyme or protein activity related to a bacterial infection in a subject, amelioration of one  
or more symptoms of a bacterial infection in a subject, or the slowing or delaying of  
progression of a bacterial infection in a subject. The language "treat," "treating" and  
35 "treatment" also includes the reduction or inhibition of the bacterial growth, replication or a  
reduction or inhibition of the bacterial load of bacteria in a subject.

The term "subject" includes, for example, primates, cows, horses, pigs, sheep,

dogs, cats, rabbits, rats, birds (including wild and domestic birds, such as turkeys, geese, chickens, ducks and the like) and mice. In some embodiments, the subject is a primate, for example, a human. In some embodiments, the subject is suffering from a Gram-positive bacterial infection. In some embodiments, the subject is suffering from a Gram-negative bacterial infection. In some embodiments, the subject is suffering from an atypical bacterial infection. In some embodiments, the subject is in need of treatment (e.g., the subject would benefit biologically or medically from treatment). In some embodiments, the subject is suffering from a significant underlying disease state that complicates the response to treatment of a bacterial infection, for example cystic fibrosis. In some embodiments, the subject is suffering from one or more bacterial infections (e.g., co-infected by two or more bacterial infections). In some embodiments, the subject is suffering from an infection caused by *Neisseria gonorrhoeae*. In some embodiments, the subject is co-infected with *Chlamydia trachomatis* and *Neisseria gonorrhoeae*. In some embodiments, the subject is at risk of contracting a sexually transmitted bacterial infection (e.g., a *Chlamydia trachomatis* or *Neisseria gonorrhoeae* infection).

The language "effective amount" includes an amount of (2*R*,4*S*,4*aS*)-11-fluoro-2,4-dimethyl-8-[(4*S*)-4-methyl-2-oxo-1,3-oxazolidin-3-yl]-1,2,4,4*a*-tetrahydro-2'*H*,6'*H*-spiro[1,4-oxazino[4,3-*a*][1,2]oxazolo[4,5-*g*]quinoline-5,5'-pyrimidine]-2',4',6'(1'*H*,3'*H*)-trione, or a pharmaceutically acceptable salt thereof, that will elicit a biological or medical response of a subject, for example, the reduction or inhibition of enzyme or protein activity related to a bacterial DNA gyrase or a bacterial infection, amelioration of symptoms of a bacterial infection, or the slowing or delaying of progression of a bacterial infection. In some embodiments, the language "effective amount" includes the amount of (2*R*,4*S*,4*aS*)-11-fluoro-2,4-dimethyl-8-[(4*S*)-4-methyl-2-oxo-1,3-oxazolidin-3-yl]-1,2,4,4*a*-tetrahydro-2'*H*,6'*H*-spiro[1,4-oxazino[4,3-*a*][1,2]oxazolo[4,5-*g*]quinoline-5,5'-pyrimidine]-2',4',6'(1'*H*,3'*H*)-trione, or a pharmaceutically acceptable salt thereof, that when administered to a subject, is effective to at least partially alleviate, inhibit, and/or ameliorate a bacterial infection or inhibit bacterial DNA gyrase, and/or reduce or inhibit the bacterial growth, replication or bacterial load of a bacteria in a subject.

30


### Exemplification

Example 1. Synthesis of (2*R*,4*S*,4*aS*)-11-fluoro-2,4-dimethyl-8-[(4*S*)-4-methyl-2-oxo-1,3-oxazolidin-3-yl]-1,2,4,4*a*-tetrahydro-2'*H*,6'*H*-spiro[1,4-oxazino[4,3-*a*][1,2]oxazolo[4,5-*g*]quinoline-5,5'-pyrimidine]-2',4',6'(1'*H*,3'*H*)-trione (Compound 1)

35 Compound 1 was synthesized as described below:

### Intermediate 1

3-Chloro-6-[(2*R*,6*S*)-2,6-dimethylmorpholin-4-yl]-7-fluoro-1,2-benzoxazole-5-carbaldehyde



To an ice cooled solution of 3-chloro-6,7-difluoro-1,2-benzoxazole-5-carbaldehyde (prepared according to the procedure described in International Application Publication No. WO 2010/043893, 5.0 g, 23.0 mmol) in anhydrous acetonitrile (50 ml) was added


5 diisopropylethylamine (5.9 g, 45.9 mmol) followed by *cis*-2,6-dimethylmorpholine (2.6 g, 23.0 mmol) and the mixture was heated at 85 °C for 12 hours in a sealed tube. The solution was cooled to room temperature and the volatiles were removed under vacuum. The the residue

10 qwas dissolved in Ethyl acetate, washed with water followed by brine and then dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. Removal of solvent under vacuum afforded the crude product, which was purified over silica gel column using a gradient of ethyl acetate in pet. ether to give title

compound as solid. Yield: 6.0 g (84%). <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>) δ: 1.0 (d, 6H), 2.9 (t, 2H), 3.1 (d, 2H), 3.8 (m, 2H), 7.7 (s, 1H), 10.2 (s, 1H). MS (ES) MH<sup>+</sup>: 313 for C<sub>14</sub>H<sub>14</sub>ClFN<sub>2</sub>O<sub>3</sub>.

### 15 Intermediate 2

3-Chloro-6-[(2*R*,6*S*)-2,6-dimethylmorpholin-4-yl]-5-(1,3-dioxolan-2-yl)-7-fluoro-1,2-benzoxazole



A solution of **Intermediate 1** (16.3 g, 52.2 mmol), ethylene glycol (8.1 g, 130.6 mmol) and


20 pyridinium *p*-toluenesulfonate (1.31 g, 5.2 mmol) in toluene (300 mL) was heated at reflux in a Dean-Stark apparatus for 16 hours. The solvents were removed under vacuum and the residue was dissolved in diethyl ether (75 mL), washed with water (3 x 25 mL) and aqueous

brine (25 mL). The organic layers were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and filtered. Removal


25 of solvents under vacuum afforded the title compound, which was further purified by trituration with hot hexane. Yield: 18.0 g (80 %). <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>) δ: 1.1 (d, 6H), 2.8 (t, 2H), 3.0 (d, 2H), 3.3 (m, 4H), 3.8 (m, 2H), 5.7 (s, 1H), 7.6 (s, 1H).

### Intermediate 3

(4*R*)-3-{6-[(2*R*,6*S*)-2,6-Dimethylmorpholin-4-yl]-5-(1,3-dioxolan-2-yl)-7-fluoro-1,2-

benzoxazol-3-yl}-4-methyl-1,3-oxazolidin-2-one


To a stirred solution of NaH (0.24 g, 9.9 mmol) in dimethylformamide (10 mL), a solution of (4*R*)-4-methyl-1,3-oxazolidin-2-one (synthesized according to the procedure described in Nishiyama, T.; Matsui, Shigeki; Yamada, F. *J. Het. Chem.* (1986), 23(5), 1427-9) (1.0 g, 9.9 mmol) in dimethylformamide (10 mL) was added slowly at 0°C over a period of 10 minutes. The mixture was stirred at the room temperature for 30 minutes and a solution of **Intermediate 2** (1.1 g, 3.1 mmol) in dimethylformamide (5 mL) was added at the same temperature. This mixture was heated at 80°C for 12 hours and poured into ice-cooled water and extracted with ethyl acetate (2 x 20 mL). The organic layers were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and the solvents were removed under vacuum. The crude product was purified by silica gel column chromatography using a gradient of ethyl acetate in pet. ether. Yield: 0.15 g (12%). MS (ES) MH<sup>+</sup>: 422.4 for C<sub>20</sub>H<sub>24</sub>FN<sub>3</sub>O<sub>6</sub>.

15 **Intermediate 4**(4S)-3-{6-[(2*R*,6*S*)-2,6-Dimethylmorpholin-4-yl]-5-(1,3-dioxolan-2-yl)-7-fluoro-1,2-benzoxazol-3-yl}-4-methyl-1,3-oxazolidin-2-one

**Intermediate 4** was prepared from **Intermediate 2** using (4*S*)-4-methyl-1,3-oxazolidin-2-one (synthesized according to the procedure described in Nishiyama, T.; Matsui, Shigeki; Yamada, F. *J. Het. Chem.* (1986), 23(5), 1427-9) in a method similar to the one described for the synthesis of **Intermediate 3**. MS (ES) MH<sup>+</sup>: 422.4 for C<sub>20</sub>H<sub>24</sub>FN<sub>3</sub>O<sub>6</sub>.


**Compound 1**

25 (2*R*,4*S*,4*aS*)-11-Fluoro-2,4-dimethyl-8-[(4*S*)-4-methyl-2-oxo-1,3-oxazolidin-3-yl]-1,2,4,4a-tetrahydro-2'*H*,6'*H*-spiro[1,4-oxazino[4,3-*a*][1,2]oxazolo[4,5-*g*]quinoline-5,5'-pyrimidine]-2',4',6'(1'*H*,3'*H*)-trione



A stirred mixture of **Intermediate 4** (0.36 mmol) and barbituric acid (0.3 mmol) in acetic acid (1 ml) was heated at 85 °C for 16 hours. The solvents were evaporated, the residue was dissolved in methanol (2 ml) and water (5 ml) was added. The precipitated solids were filtered and purified by reverse phase HPLC (10 mM ammonium acetate in water, CH<sub>3</sub>CN), eluting two components. The second eluting component was isolated as a solid and identified as the title compound. The title compound was isolated by reverse phase HPLC (10 mM ammonium acetate in water, CH<sub>3</sub>CN) as the first eluting of two components. <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>) δ: 0.9 (d, 3H), 1.15 (d, 3H), 1.4 (d, 3H), 2.9 (d, 1H), 3.1 (t, 1H), 3.5-3.6 (m, 2H), 3.8 (m, 1H), 3.9 (d, 1H), 4.0 (d, 1H), 4.2 (q, 1H), 4.6-4.7 (m, 2H), 7.6 (s, 1H), 11.5 (s, 1H), 11.8 (s, 1H). MS (ES) MH<sup>+</sup>: 488.4 for C<sub>22</sub>H<sub>22</sub>FN<sub>5</sub>O<sub>7</sub>; [α]<sub>D</sub><sup>20</sup> = -92 (c = 1; MeOH).

Also isolated from the synthesis of **Compound 1** as the second eluting component from HPLC purification was (2*S*,4*R*,4*aR*)-11-fluoro-2,4-dimethyl-8-[(4*S*)-4-methyl-2-oxo-1,3-oxazolidin-3-yl]-1,2,4,4*a*-tetrahydro-2'*H*,6*H*-spiro[1,4-oxazino[4,3-*a*][1,2]oxazolo[4,5-*g*]quinoline-5,5'-pyrimidine]-2',4',6'(1'*H*,3'*H*)-trione



<sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>) δ: 0.9 (d, 3H), 1.15 (d, 3H), 1.4 (d, 3H), 2.9 (d, 1H), 3.1 (t, 1H), 3.6-3.7 (m, 2H), 3.8-4.0 (m, 1H), 3.9 (d, 1H), 4.1 (d, 1H), 4.2 (q, 1H), 4.6-4.7 (m, 2H), 7.6 (s, 1H), 11.5 (s, 1H), 11.8 (s, 1H). MS (ES) MH<sup>+</sup>: 488.4 for C<sub>22</sub>H<sub>22</sub>FN<sub>5</sub>O<sub>7</sub>; [α]<sub>D</sub><sup>20</sup> = +224 (c = 1; MeOH).

#### Example 2. *In Vitro* Antibacterial Activity of Compound 1 against Human Mycoplasmas

Compound 1 is an investigational inhibitor of the supercoiling and decatenation activity of the DNA gyrase and topoisomerase IV with activities against several different types of bacteria. Preliminary data suggest this agent maintains activity against organisms that are resistant to other agents such as fluoroquinolones and tetracyclines, including

agents of sexually transmitted infections such as *Neisseria gonorrhoeae*. The present study was undertaken to increase knowledge of the *in vitro* activities of Compound 1 against additional human pathogens by testing a small number of clinical isolates and reference strains representing five species of mollicutes that are important human pathogens.

5 Organisms tested included *Mycoplasma pneumoniae*, *Mycoplasma hominis*, *Mycoplasma genitalium*, *Ureaplasma urealyticum* and *Ureaplasma parvum*. While *M. pneumoniae* is primarily a pathogen of the respiratory tract causing illnesses such as pharyngitis, tracheobronchitis, and pneumonia, the remaining species are important pathogens of the urogenital tracts in adult men and women and can also cause systemic disease in neonates  
 10 when transmitted vertically during pregnancy or at delivery. Susceptibility testing was performed in accordance with guidelines of the Clinical Laboratory Standards Institute (CLSI) (CLSI 2011). Strains tested included organisms that contained the tetM gene, which mediates tetracycline resistance, mutations in 23S ribosomal RNA that confers macrolide resistance, and others that contained mutations in DNA gyrase and/or topoisomerase IV that  
 15 confer resistance to fluoroquinolones.

## METHODS

**Antibacterials.** Drugs included in the investigation are summarized in Table 1. An appropriate amount of each powdered drug was weighed to prepare 10 mL of a stock  
 20 solution, allowing for the percentage purity of each. Antimicrobial agents were dissolved according to each manufacturer's instructions.

**Table 1. Test Compound and Control/Reference Compounds**

Compound	Purity	Source
Compound 1	98.9%	
Azithromycin	95.2%	Fluka/Sigma-Aldrich Switzerland
Doxycycline	100%	Sigma-Aldrich St. Louis, MO
Levofloxacin	99%	Sigma-Aldrich St. Louis, MO

25 **Bacterial strains.** Pure cultures of clinical isolates of known titer derived from various body sites of adults and children that have been stored at minus 70 °C in the culture collections of the UAB Diagnostic Mycoplasma Laboratory were used in this investigation. Original sources of the isolates and year of isolation, when available, as well as specific resistance profiles,

where relevant, are summarized in Table 2.

**Table 2. Bacterial Strains Tested**

*Mycoplasma genitalium* (n - 5)

Accession No. or stock identifier	Year Isolated	Body Site Strain Designation	Comment
M2341	unknown	Urethra	Danish male with NGU
M30	1980	Urethra ATCC 49895	British male with NGU
M2321	unknown	Urethra	Danish male with NGU
M6282	unknown	Urethra	Japanese male with NGU
UTMB-10G	1986	Synovial fluid ATCC 49899	Texas male with pneumonia and arthritis
G37 QC Strain ATCC 33530	1980	Urethra	British male with NGU

*Mycoplasma pneumoniae* (n - 12)

Accession No. or stock identifier	Year Isolated	Body Site Strain Designation	Comment
54484	2009	Throat	UAB Clinical isolate Macrolide-resistant
54506	2009	BAL	UAB Clinical isolate Macrolide-resistant
55246	2010	Throat	UAB Clinical isolate
55612	2010	Sputum	UAB Clinical isolate
57807	2012	BAL	UAB Clinical isolate
58188	2012	BAL	UAB Clinical isolate
58772	2012	BAL	UAB Clinical isolate
59598	2013	BAL	UAB Clinical isolate
59597	2013	BAL	UAB Clinical isolate
53938	2009	BAL	UAB Clinical isolate
53706	2009	BAL	UAB Clinical isolate
51494	2006	CSF	UAB Clinical isolate
M-129 QC Strain ATCC 29342-B7	unknown	Respiratory tract	Patient with pneumonia

*Mycoplasma hominis* (n = 12)

Accession No. or stock identifier	Year Isolated	Body Site	Comment
10848	1991	Endometrium	UAB Clinical isolate Contains <i>tetM</i>
10505	1991	Endometrium	UAB Clinical isolate Contains <i>tetM</i>
59793	2013	Cervix	UAB Clinical isolate
59744	2013	Cervix	UAB Clinical isolate
58881	2012	unknown	UAB Clinical isolate
58603	2012	Vagina	UAB Clinical isolate
11124	1991	Endometrium	UAB Clinical isolate
11063	1991	Endometrium	UAB Clinical isolate
11140	1991	Endometrium	UAB Clinical isolate Contains <i>tetM</i> gene
11121	1991	Endometrium	UAB Clinical isolate
11612	1991	Endometrium	UAB Clinical isolate
12434	1992	Endometrium	UAB Clinical isolate
PG21 QC Strain ATCC 23114	unknown	Rectal swab	

*Ureaplasma* species (n - 15)

Accession No. or stock identifier	Species	Year Isolated	Body Site	Comment
25353	Uu	1997	Pleural fluid	UAB Clinical isolate Contains <i>tetM</i> , Fluoroquinolone and- Macrolide-resistant
48105	Up	2001	Vagina	Fluoroquinolone-resistant
48736	Up	2002	unknown	UAB Clinical isolate
51110	Up	2005	unknown	UAB Clinical isolate Fluoroquinolone-resistant
49718	Uu	2003	unknown	UAB Clinical isolate Contains <i>tetM</i>
50826	Uu	2005	unknown	UAB Clinical isolate Contains <i>tetM</i>
43306	Uu	1999	Tissue	UAB Clinical isolate
44062	Uu	1999	Vagina	UAB Clinical isolate
45623	Up	2000	ETA	UAB Clinical isolate
48750	Up	2002	Rectal swab	UAB Clinical isolate
52863	Up	2008	ETA	UAB Clinical isolate
59913	Up/Uu	2013	Urethra	UAB Clinical isolate
59967	Up	2013	Urethra	UAB Clinical isolate
60052	Up/Uu	2013	Urethra	UAB Clinical isolate
60153	Up/Uu	2013	Vagina	UAB Clinical isolate Fluoroquinolone-resistant
Uu Serotype 9 QC Strain ATCC 33175	Uu	unknown	Urethra	Canadian male with NGU Contains <i>tetM</i>

### Notes for Table 2

Abbreviations: Uu = *Ureaplasma urealyticum*, Up = *Ureaplasma parvum*, BAL = bronchoalveolar lavage fluid, CSF = cerebrospinal fluid, ETA = endotracheal aspirate

*Ureaplasma* species were identified by real-time PCR as previously described (Xiao *et al.* Detection and characterization of human *Ureaplasma* species and serovars by real-time PCR. *J. Clin. Microbiol.* 2010,48, 2715-2723). Three clinical isolates were shown to be a mixture of both species, which sometimes occurs (Xiao *et al.* Extensive horizontal gene transfer in ureaplasmas from humans questions the utility of serotyping for diagnostic purposes. *J. Clin. Microbiol.* 2011, 49, 2818-2826).

Presence of *tetM* in *M. hominis* and *Ureaplasma* species was determined by PCR in the UAB Diagnostic Mycoplasma Laboratory.

### ***In vitro* susceptibility test methods:**

The assay employed for this investigation was the broth microdilution minimal inhibitory concentration (MIC) assay that was published in "Methods for Antimicrobial Susceptibility Testing of Human Mycoplasmas. Approved Guideline, CLSI Document M43-A" (CLSI 2011). This assay employs 96 well microtiter plates into which a defined inoculum of the organism to be tested is added to doubling dilutions of antimicrobial agents in small volumes. Plates were incubated until the growth control changed color. The MIC endpoint was then determined by lack of color change in broth containing a pH indicator. Specific aspects of the procedures that were used follow.

**Media.** SP4 broth and SP4 agar were used for testing *M. pneumoniae* and *M. genitalium*. Modified Hayflick's *Mycoplasma* broth and agar were used for testing *M. hominis*. Shepard's 10B Broth and A8 agar were used for testing *Ureaplasma* species. These media and their formulations are described in the CLSI document (CLSI 2011).

**Preparation of Inoculum.** Organisms were thawed to room temperature and diluted in appropriate prewarmed media in 50 mL conical tubes to yield a final inoculum of approximately  $10^4$  CFU/mL. At least 5 mLs of inoculum was prepared for each drug, based on testing 8 dilutions in duplicate and appropriate controls. If more dilutions were needed to achieve endpoint MICs, an additional volume of inoculum was prepared. Inoculated broths were incubated aerobically at 37 °C for 2 hours prior to use to allow mycoplasmas to become metabolically active prior to inoculating microtiter plates. Due to their more rapid growth rates, ureaplasmas were incubated for only one hour prior to inoculating the plates.

**Performance of Broth Microdilution Assay.** A single microtiter plate was used for 4 drugs. Each drug was tested in duplicate (Drug 1-rows A, B; Drug 2-rows C, D; Drug 3-rows E, F. Wells 9, 10, 11 and 12 were used for solvent, media, drug and growth controls, respectively. 0.025 mL of appropriate broth medium was added to rows 2-8 and 10 and 12 of

the microtiter plate. 0.025 mL of the highest concentration of drug to be tested was added to wells 1, 2 and 11 in rows A, B. Well 11 served as the drug control. The other drugs to be tested were added the same way in their respective rows. The highest drug concentration was prepared by performing an appropriate dilution on the stock solution. Antimicrobial agents were serially diluted using a 0.025 mL multichannel pipette, beginning at the 2nd well, and continuing through well 8, discarding the final 0.025 mL. A solvent control was prepared in well 9 by incorporating 0.025 mL of the highest concentration (1:10 dilution in sterile deionized water) of solvent used to dissolve the antimicrobial agent being tested if any substance other than water was used as a solvent. 0.175 mL of the desired dilution of inoculated media that has been prewarmed for 2 hours was added to each well in rows 1-9 and 12. Well 12 served as the growth control. Inocula were added starting with well 12 and working backwards to well 1 to prevent drug carryover. 0.175 mL of appropriate uninoculated media was added to wells 10 and 11 (total of 0.2 mL) for media and drug controls. A final determination of the CFU/mL of the working dilution used to inoculate each microtiter plate was made by preparing 6 serial dilutions of the inoculum (0.1 mL inoculum in 0.9 mL of the appropriate broth) and pipetting 20  $\mu$ l of each dilution onto the appropriate agar plate to check that a proper dilution was made and that the inoculum contained  $10^4$ - $10^5$  CFU/mL. Agar plates were incubated at 37 °C in air plus 5% CO<sub>2</sub> until colonies were visible and could be counted. Time required until growth becomes visible varies according to species, ranging from 24-72 hours for *Ureaplasma* species and *M. hominis* up to several days for *M. pneumoniae* and *M. genitalium*. Microdilution trays were incubated aerobically at 37 °C and examined after 18-24 hours and then daily for color change in the growth control wells.

**Determination of MIC Endpoints, Quality Control, and Assay Validation.** MICs were recorded as the lowest concentration of antimicrobial agent inhibiting color change in broth medium at the time when the organism control well first showed color change. A positive reaction for growth of *Ureaplasma* spp. in 10B broth was evidenced by a color change from yellow to pink in the organism control well (*i.e.* well 12). A positive reaction for *M. hominis* in Mycoplasma broth was evidenced by a color change from pink to deeper red in the organism growth control well (*i.e.* well 12). A positive reaction for *M. pneumoniae* and *M. genitalium* in SP4 broth was evidenced by a color change from pink to yellow in the growth control well. Results were considered valid if the control agar plate for organism's concentration indicated that there were between  $10^4$  and  $10^5$  CFU/mL. Control wells and expected results were: well 9 (solvent control) – no color change; well 10 (media control) – no color change; well 11 (drug control) – no color change; well 12 (growth control) – growth and color change according to which organism is being tested, without turbidity. By performing CFU quantification on the inoculum of each isolate tested, purity of the organisms was verified. SP4 agar detects contaminants or mixed cultures with *Mycoplasma* species

when inoculated with *M. pneumoniae* and *M. genitalium*. *M. hominis* grows on either SP4 or mycoplasma agar. *M. hominis* and commensal respiratory *Mycoplasma* species produce fried egg colonies whereas; *M. pneumoniae* and *M. genitalium* produce small spherical colonies. A8 agar plates yield brown granular colonies for *Ureaplasma* species and would also detect contaminating *Mycoplasma* species or bacteria. Any turbidity in the growth control well indicates bacterial contamination and invalidates the results.

**Broth Microdilution MIC Quality Control Limits.** For quality control (QC) purposes, American Type Culture Collection (ATCC) strains designated by the CLSI (CLSI 2011) for each organism being tested were included with each assay every day of performance. MIC reference ranges for several antimicrobial agents have been established for these strains (CLSI 2011). QC strains that were used were: *M. pneumoniae* ATCC 29342, *M. hominis* ATCC 23114, and *U. urealyticum* ATCC 33175. There is no *M. genitalium* type strain recommended by the CLSI since susceptibility testing has not been standardized for this organism. Therefore, we chose the type strain ATCC 33530 for this organism. This strain has been used in our laboratory for other investigations and has predictable MICs for several antimicrobial agents. Acceptable MIC QC limits for a single test (single-drug/single organism combination) are listed in Table 3 as derived from the CLSI document (CLSI 2011). QC strains performed as expected for all MIC assays for which data are presented.

**Table 3. MIC Limits ( $\mu\text{g}/\text{mL}$ ) for Quality Control Strains for *Mycoplasma hominis*, *Mycoplasma pneumoniae* and *Ureaplasma urealyticum* Tested by Broth Microdilution**

Antimicrobial Agent	<i>Mycoplasma hominis</i> ATCC 23114	<i>Mycoplasma pneumoniae</i> ATCC 29342	<i>Ureaplasma urealyticum</i> ATCC 33175
Azithromycin	--	--	0.5 – 8
Clindamycin	0.0032 – 0.25	0.25 – 4	2 – 32
Erythromycin	--	0.004 – 0.063	1 - 8
Levofloxacin	0.032 – 0.5	0.125 - 1	0.5 - 2
Moxifloxacin	0.016 – 0.125	0.032 – 0.25	0.5 - 2
Telithromycin	--	--	0.125 - 1
Tetracycline	--	0.063 – 1	16 – 256

**Note for Table 3**

Data in Table 3 were derived from the M-43-A CLSI Document (CLSI 2011).

**25 RESULTS**

*M. genitalium*. Compound 1 showed *in vitro* activity comparable to that of levofloxacin and doxycycline. The overall MIC range for these three drugs was within 4 2-fold dilutions = 0.25-2  $\mu\text{g}/\text{mL}$ . Compound 1 MIC range 0.5-1  $\mu\text{g}/\text{mL}$ ) was less potent than azithromycin (MIC range < 0.001  $\mu\text{g}/\text{mL}$ ).

*M. pneumoniae*. The MIC<sub>90</sub> for Compound 1 (1 µg/mL) was equivalent to that of levofloxacin and 4-fold higher than doxycycline (0.25 µg/mL). Most *M. pneumoniae* isolates had azithromycin MICs < 0.001 µg/mL, but two strains were chosen for testing because they had azithromycin MICs of 16 and 32 µg/mL and contained mutations in 23S ribosomal RNA.

5 Compound 1 maintained *in vitro* potency against these two macrolide-resistant isolates comparable to that for those isolates that were fully macrolide-susceptible.

*M. hominis*. Compound 1 had the lowest overall activity against *M. hominis* with the MIC<sub>90</sub> of 4 µg/mL and a maximum MIC value of 8 µg/mL. Doxycycline MICs for *M. hominis* isolates without tetM ranged from 0.016-0.063 µg/mL, while MICs for those three with tetM  
10 were 4 µg/mL. Corresponding tetracycline MICs were 32 µg/mL for those isolates. Compound 1 MICs for doxycycline not affected by the presence of tetM. MIC<sub>90</sub> for Compound 1 (4 µg/mL) was 16-fold greater than that of levofloxacin (0.25 µg/mL) and was equivalent to that of azithromycin, a drug that is not usually very active against this species. Without having information on achievable drug concentrations for Compound 1, it is not  
15 possible to indicate whether these MICs would be considered susceptible or resistant.

*Ureaplasma species*. The MIC<sub>90</sub> for Compound 1 was 1 µg/mL, making it comparable to levofloxacin in potency. There was no difference in Compound 1 MICs against levofloxacin-resistant ureaplasmas and levofloxacin-susceptible isolates. Similarly, among three *Ureaplasma* isolates containing tetM, MICs for Compound 1 were not affected  
20 with its MICs ranging from 0.5-2 µg/mL versus 4-8 µg/mL for doxycycline, but MIC<sub>90</sub> for doxycycline-susceptible organisms (0.125 µg/mL) was 8-fold more active than Compound 1 (1 µg/mL). The Compound 1 MIC for the single macrolide-resistant isolate of *U. urealyticum* (azithromycin MIC = 32 µg/mL) was 2 µg/mL, which was 2-fold dilution higher than the MIC<sub>90</sub> for this drug, but overall, Compound 1 was 4-fold more potent than azithromycin (MIC<sub>90</sub> of 1  
25 vs 4 µg/mL).

**Table 4. MIC Dataset for Compound 1 and Three Comparators Tested Against Human Mycoplasmas***Mycoplasma genitalium* (n = 5) MICs ( $\mu\text{g/mL}$ )

Accession No. or stock identifier	Compound 1	AZI	DOX	LEV
M2341	0.5	<0.001	1	0.5
M30	1	<0.001	0.25	2
M2321	0.5	<0.001	1	0.5
M6282	0.5	<0.001	1	0.5
UTMB-10G	0.5	<0.001	0.5	2
G37 QC Strain ATCC 33530	0.5	<0.001	0.25	2

5 *Mycoplasma pneumoniae* (n - 12) MICs ( $\mu\text{g/mL}$ )

Accession No. or stock identifier	Compound 1	AZI	DOX	LEV
54484	0.5	32	0.25	0.5
54506	0.5	16	0.25	0.5
55246	1.0	<0.001	0.25	1
55612	1.0	<0.001	0.25	0.5
57807	0.5	<0.001	0.25	0.5
58188	0.5	<0.001	0.125	0.5
58772	0.5	<0.001	0.5	1
59598	0.5	<0.001	0.25	1
59597	0.5	<0.001	0.25	0.5
53938	0.5	<0.001	0.25	1
53706	0.5	<0.001	0.25	0.5
51494	0.5	<0.001	0.25	1
M-129 QC Strain ATCC 29342-B7	0.5	<0.001	0.5	1

*Mycoplasma hominis* (n = 12) MICs ( $\mu\text{g/L}$ )

Accession No. or stock identifier	Compound 1	AZI	DOX	LEV
10848	8	8	4	0.25
10505	2	4	4	0.063
59793	2	4	0.032	0.25
59744	2	2	0.016	0.125
58881	4	4	0.032	0.25
58603	1	1	0.032	0.125
11124	2	1	0.032	0.25
11063	4	4	0.063	0.125
11140	4	1	4	0.125
11121	1	4	0.032	0.125
11612	4	4	0.016	0.25
12434	4	2	0.032	0.125
PG21 QC Strain ATCC 23114	2	1	0.032	0.5

*Ureaplasma* species (n - 15) MICs ( $\mu\text{g/mL}$ )

Accession No. or stock identifier	Species	Compound 1	AZI	DOX	LEV
25353	Uu	2	32	8	8
48105	Up	0.5	2	0.125	32
48736	Up	0.5	1	0.063	1
51110	Up	0.5	1	0.016	8
49718	Uu	1	2	8	1
50826	Uu	0.5	2	4	0.5
43306	Uu	1	4	0.125	1
44062	Uu	1	4	0.25	1
45623	Up	0.25	1	0.016	0.25
48750	Up	0.125	1	2	0.25
52863	Up	0.5	2	0.125	1
59913	Up/Uu	0.5	2	0.125	1
59967	Up	0.5	4	0.063	1
60052	Up/Uu	0.5	2	0.125	1
60153	Up/Uu	0.5	2	0.063	4
Uu Serotype 9 QC Strain ATCC 33175	Uu	0.5	2	8	1

Table 5. Data Summary for Compound 1 and Three Comparators Tested Against Human Mycoplasmas

<i>M. genitalium</i> MICs (µg/mL) n = 5	Compound 1	Azithromycin	Doxycycline	Levofloxacin
Range	0.5-1	<0.001	0.25-1	0.5-2
M2341	0.5	<0.001	1	0.5
M30	1	<0.001	0.25	2
M2321	0.5	<0.001	1	0.5
M6282	0.5	<0.001	1	0.5
UTMB	0.5	<0.001	0.5	2
G37 QC Strain ATCC 33530	0.5	<0.001	0.25	2
<i>M. pneumoniae</i> MICs (µg/mL) n=12	Compound 1	Azithromycin	Doxycycline	Levofloxacin
Range	0.5-1	<0.001-32	0.125-0.5	0.5-1
MIC <sub>50</sub>	0.5	<0.001	0.25	0.5
MIC <sub>90</sub>	1	16	0.25	1
M-129-B7 QC Strain ATCC 29342	0.5	<0.001	0.5	1
<i>M. hominis</i> MICs (µg/mL) n=12	Compound 1	Azithromycin	Doxycycline	Levofloxacin
Range	1-8	1-8	0.016-4	0.063-0.25
MIC <sub>50</sub>	2	4	0.032	0.125
MIC <sub>90</sub>	4	4	4	0.25
PG21 QC Strain ATCC 23114	2	1	0.032	0.5
<i>Ureaplasma</i> species (µg/mL) n=15	Compound 1	Azithromycin	Doxycycline	Levofloxacin
Range	0.125-2	1-32	0.016-8	0.25-32
MIC <sub>50</sub>	0.5	2	0.125	1
MIC <sub>90</sub>	1	4	8	8
Uu Serotype 9 QC Strain ATCC 33175	0.5	2	8	1

5

**Notes for Tables 4 and 5**

Abbreviations: AZI = azithromycin, DOX = doxycycline, LEV = levofloxacin, Uu = *Ureaplasma urealyticum*, Up = *Ureaplasma parvum*.

- 10 The 3 *M. hominis* isolates containing the tetM gene were also tested against tetracycline at the same time as doxycycline. All 3 isolates had MICs of 32 µg/mL for tetracycline.

## Discussion

*Mycoplasma* and *Ureaplasma* species that infect humans can cause significant disease in the respiratory tracts as well as the urogenital tracts. In addition to *N. gonorrhoeae* and *Chlamydia trachomatis*, both *M. genitalium* and *Ureaplasma urealyticum* can cause male urethritis and *M. genitalium* also causes female cervicitis and pelvic inflammatory disease (Waites KB, Taylor-Robinson D. *Mycoplasma and Ureaplasma. Manual of Clinical Microbiology*, 10th Ed. Washington, D.C., ASM Press: 970-985, 2011). Invasive infections of the bloodstream, CSF, and lungs sometimes occur due to *M. hominis* and *Ureaplasma* species in neonates (Waites and Taylor-Robinson 2011). Invasive disease may also occur in adults in the setting of immunodeficiency (Waites and Taylor-Robinson 2011).

Treatment options for mycoplasmal and ureaplasma infections are no longer clear-cut since macrolide resistance is becoming very common in *M. pneumoniae* in Asia and is spreading gradually to Europe and North America; tetracycline resistance rates may approach 50% in *M. hominis* and *Ureaplasma* species in some areas; and resistance to macrolides and fluoroquinolones has been well documented among the genital mycoplasmas (Waites KB, Lysynyansky I, Bebear CM. (2014). Emerging antimicrobial resistance in mycoplasmas of humans and animals. *Mollicutes Molecular Biology and Pathogenesis*. G. Browning and C. Citti. Norfolk, UK, Caister Academic Press: 289-322). Patients who are immunosuppressed and those who have received numerous courses of antibiotics over time are at greater risk for having infections with drug-resistant organisms (Waites 2014). For these reasons, new agents that are not affected by cross-resistance to other drug classes such as macrolides, tetracyclines, and fluoroquinolones are needed.

This small preliminary study has demonstrated that Compound 1 has *in vitro* activity against *M. genitalium*, *M. pneumoniae*, *U. urealyticum* and *U. parvum* that is comparable to levofloxacin, another agent targeting DNA replication, and its potency was unaffected by presence of mutations conferring fluoroquinolone resistance. Furthermore, resistance to macrolides and tetracyclines in *Mycoplasma* and *Ureaplasma* species appeared not to have any significant measurable effect on MICs of Compound 1, though more isolates should be tested to confirm this observation. Azithromycin was the most potent agent tested against *M. genitalium* and *M. pneumoniae* in the absence of mutations that affect macrolide binding to the ribosomes. The MIC<sub>90</sub> for Compound 1 was 4-fold less than azithromycin against *Ureaplasma* species, making it the most active drug among the four agents tested.

## Conclusions

- Compound 1 activity *in vitro* against *M. pneumoniae*, *M. genitalium* and *Ureaplasma* species was similar overall to levofloxacin with all MICs < 2 µg/mL, while its potency against *M. hominis* was somewhat less in terms of MIC<sub>90</sub> (4 µg/mL).
- 5 • The MIC<sub>90</sub> (1 µg/mL) of Compound 1 was 4-fold lower than that of azithromycin against *Ureaplasma* species, making it the most potent of the four agents tested against these organisms.
- The activity of Compound 1 *in vitro* against *M. pneumoniae*, *M. hominis* and *Ureaplasma* species was not affected by mutations conferring macrolide or  
10 fluoroquinolone resistance, or by the presence of tetM in the small number of isolates tested.
- Compound 1 may be a potentially useful agent for further development as a possible treatment for infections caused by human mycoplasmas and ureaplasmas in the urogenital tract or respiratory tract.

15

### Example 3. In Vitro Antibacterial Activity of Compound 1 against Potential Agents of Bioterrorism

The potential of Category A and B Select Agents for use as agents of bioterrorism is well documented. To this end, we established antimicrobial susceptibility profiles for  
20 compounds from multiple drug classes and for Compound 1 against multiple isolates each of *Bacillus anthracis* (*B. anthracis*), *Burkholderia mallei* (*B. mallei*), *Burkholderia pseudomallei* (*B. pseudomallei*), *Brucella abortus* (*B. abortus*), *Brucella melitensis* (*B. melitensis*), *Brucella suis* (*B. suis*), *Francisella tularensis* (*F. tularensis*) and *Yersina pestis* (*Y. pestis*). Testing was conducted in a broth microdilution assay format following Clinical and Laboratory  
25 Standards Institute (CLSI) guidelines. Results were reported as the lowest concentration (µg/mL) of antimicrobial agent that completely inhibited growth of the organism in the microdilution wells visually.

## MATERIALS AND METHODS

### 30 Antibacterials

Three (3) comparator compounds (doxycycline, levofloxacin and chloramphenicol) and Compound 1 were screened for antibacterial activity against multiple isolates each of  
*Bacillus anthracis* (*B. anthracis*), *Burkholderia mallei* (*B. mallei*), *Burkholderia pseudomallei* (*B. pseudomallei*), *Brucella abortus* (*B. abortus*), *Brucella melitensis* (*B. melitensis*), *Brucella*  
35 *suis* (*B. suis*), *Francisella tularensis* (*F. tularensis*) and *Yersina pestis* (*Y. pestis*). Compounds were prepared according to instructions provided by the Sponsor and in accordance with CLSI guidelines. A total of 12 concentrations each for all test and

comparator compounds were tested in triplicate. The concentration range was a two-fold dilution scheme with a starting concentration of 64 µg/mL and an ending concentration of 0.031 µg/mL.

5 **Bacterial strains**

Ten isolates each of *B. anthracis*, *Y. pestis*, *B. mallei*, *B. pseudomallei*, *B. suis*, *B. melitensis*, *B. abortus* and 3 isolates of *F. tularensis* were utilized for drug screening (Table 6). In addition, the following quality control strains were included: *E. coli* 25922, *S. aureus* 29213, *P. aeruginosa* 27853, *S. pneumoniae* 49619 and *E. coli* 35218.

10

**Table 6. Bacterial Isolates Screened**

<i>Bacillus anthracis</i>	Ames	<sup>1</sup> Health Protection Agency Culture Collections; Porton Down, UK	
	36		
	38		
	41		
	46		
	411		<sup>2</sup> BEI Resources; Manassas, VA
	412		
	413		
	415		
120	<sup>1</sup> Health Protection Agency Culture Collections; Porton Down, UK		
3708			
3709			
10229			
10230			
10245		<sup>2</sup> BEI Resources; Manassas, VA	
10247			
10248			
10260			
12938			
<i>Burkholderia pseudomallei</i>	1688	<sup>1</sup> Health Protection Agency Culture Collections; Porton Down, UK	
	4845		
	4846		
	6700		
	7383		<sup>2</sup> BEI Resources; Manassas, VA
	7431		
	8016		
	8707		
	8708		
10274			
<i>Brucella abortus</i>	624	<sup>1</sup> Health Protection Agency Culture Collections; Porton Down, UK	
	1408		
	3605		
	4487		
	5059		<sup>2</sup> BEI Resources; Manassas, VA
	7470		
	7471		
7472			

	8038		
	8200		
	3511		
	3605		
	8200		
<i>Brucella melitensis</i>	8223	<sup>1</sup> Health Protection Agency Culture Collections; Porton Down, UK	
	8334		
	8631		
	8632	<sup>2</sup> BEI Resources; Manassas, VA	
	10200		
	10502		
	11361		
<i>Brucella suis</i>	3142	<sup>1</sup> Health Protection Agency Culture Collections; Porton Down, UK	
	3143		
	4490		
	5061		
	10095	<sup>2</sup> BEI Resources; Manassas, VA	
	10098		
	10385		
	10510		
	10511		
10364			
<i>Francisella tularensis</i>	643	<sup>1</sup> Health Protection Agency Culture Collections; Porton Down, UK	
	644		
	645	<sup>2</sup> BEI Resources; Manassas, VA	
<i>Yersinia Pestis</i>	CO92	<sup>1</sup> Health Protection Agency Culture Collections; Porton Down, UK	
	16		
	17		
	20	<sup>2</sup> BEI Resources; Manassas, VA	
	637		
	639		
	640		
	8775		<sup>3</sup> Lovelace Respiratory Research Institute; Albuquerque, NM
	10029		
10030			

#### ***In vitro* susceptibility test methods (as appropriate)**

Testing was conducted utilizing the broth microdilution methodology outlined by CLSI guidelines. Briefly, testing was conducted using 96-well, U-bottom microplates with an assay volume of 0.2 mL/well. Plates containing appropriate broth and two-fold dilutions of the test compounds were inoculated with a targeted concentration of  $5.0 \times 10^5$  CFU/mL ( $5.0 \times 10^4$  CFU/well) of bacterial agent and subsequently incubated for 24 -72 hours depending on the agent. Following incubation, the plates were read visually and individual wells scored for turbidity, partial clearing or complete clearing. The MIC was reported as the lowest concentration ( $\mu\text{g/mL}$ ) of drug that visually inhibited growth of the organism. Growth medium, inoculum preparation and incubation conditions are provided below in Table 7.

Table 7. Growth Medium, Inoculum Preparation and Incubation Conditions

Organism	Medium	Inoculum	Incubation
<i>Bacillus anthracis</i>	CAMHB	Direct Colony Suspension	37 °C, ~18 hours
<i>Brucella abortus</i>	Brucella Broth pH 7.1 ±0.1	Growth Method	37 °C, 48 hours
<i>Brucella melitensis</i>	Brucella Broth pH 7.1 ±0.1	Growth Method	37 °C, 48 hours
<i>Brucella suis</i>	Brucella Broth pH 7.1 ±0.1	Growth Method	37 °C, 48 hours
<i>Burkholderia mallei</i>	CAMHB	Growth Method	37 °C, ~18 hours
<i>Burkholderia pseudomallei</i>	CAMHB	Growth Method	37 °C, ~18 hours
<i>Francisella tularensis</i>	CAMHB + 2% IsoVitaleX™	Direct Colony Suspension	37 °C, 48-72 hours
<i>Yersinia pestis</i>	CAMHB	Growth Method	28 °C, 24-48 hours

The results of the screen described above are shown in Table 8 and 9.

5 Table 8. Antimicrobial Susceptibility of Compound 1 and Three Comparators Against Select Bacteria

Organism	Compound 1 MIC (µg/mL)	Doxycycline MIC (µg/mL)	Chloramphenicol MIC (µg/mL)	Levofloxacin MIC (µg/mL)
<i>Burkholderia pseudomallei</i>	32	0.5	16	4
	32	0.5	8	2
	32	0.5	8	2
	64	0.5	16	4
	32	0.063	4	4
	32	0.5	16	4
	32	8	>256	16
	32	0.25	8	8
	64	0.25	8	4
	32	8	64	8
<i>Burkholderia mallei</i>	4	≤ 0.031	4	0.5
	0.25	≤ 0.031	1	≤ 0.125
	4	≤ 0.031	4	0.25
	64	≤ 0.031	1	0.5
	32	0.063	8	0.5

	2	≤ 0.031	8	≤ 0.125
	8	≤ 0.031	4	≤ 0.125
	0.5	≤ 0.031	1	≤ 0.125
	2	≤ 0.031	4	0.5
	2	0.063	4	0.25
<i>Brucella abortus</i>	8	0.25	1	0.5
	4	0.25	1	0.25
	8	0.125	1	0.25
	4	0.125	2	0.25
	4	0.25	2	0.25
	0.063	0.063	0.5	0.25
	1	0.25	2	0.25
	0.5	0.063	1	0.25
	1	0.063	2	0.25
<i>Yersinia pestis</i>	16	0.5	4	0.5
	2	0.5	4	≤ 0.25
	2	0.5	8	≤ 0.25
	2	0.5	8	≤ 0.25
	>64	1	8	0.25
	2	1	4	≤ 0.25
	2	1	2	≤ 0.25
	2	0.5	8	≤ 0.25
	1	0.5	8	0.25
	2	0.5	8	≤ 0.25
<i>Francisella tularensis</i>	2	1	8	≤ 0.25
	16	4	2	≤ 0.125
	8	1	2	≤ 0.125
<i>Bacillus anthracis</i>	16	2	1	≤ 0.125
	0.5	≤ 0.031	8	≤ 0.25
	0.125	≤ 0.031	8	≤ 0.25
	0.125	≤ 0.031	4	≤ 0.25
	0.25	≤ 0.031	8	≤ 0.25
	0.5	≤ 0.031	4	≤ 0.25
	0.125	≤ 0.031	8	≤ 0.25
	1	≤ 0.031	8	≤ 0.25
	0.5	≤ 0.031	8	≤ 0.25
	0.05	≤ 0.031	8	≤ 0.25
0.125	≤ 0.031	8	≤ 0.25	
<i>Brucella melitensis</i>	8	0.25	4	0.5
	8	0.125	2	0.5
	16	0.25	8	1
	8	0.25	4	0.25
	8	0.125	4	0.5

	8	0.125	4	0.5
	8	0.125	4	0.5
	8	0.125	2	0.25
	8	0.125	4	0.5
	16	0.125	4	0.5
<b><i>Brucella suis</i></b>	2	0.063	2	0.5
	1	0.063	1	0.25
	1	0.063	1	0.5
	1	0.125	2	0.5
	1	0.063	2	0.5
	2	0.125	2	0.25
	1	0.063	4	0.5
	1	0.063	2	0.5
	1	0.063	1	0.25
	1	0.063	2	0.5

Table 9. *In vitro* activity of Compound 1 ( $\mu\text{g/ml}$ )

Organism	N	Range	MIC <sub>50</sub>	MIC <sub>90</sub>
<i>Bacillus anthracis</i>	10	0.12-1	0.25	0.5
<i>B. anthracis</i>	30	0.12-4	0.25	1
<i>Brucella suis</i>	10	1-2	1	2
<i>Burkholderia mallei</i>	10	0.25-64	2	32
<i>B. mallei</i>	30	2-32	16	32
<i>Burkholderia pseudomallei</i>	10	32-64	32	64
<i>B. pseudomallei</i>	28	32->32	32	>64
<i>Francisella tularensis</i>	27	8-16	16	16
<i>Yersinia pestis</i>	10	1->64	2	2
<i>Y. pestis</i>	30	2-8	4	8

**Claims**

1. A method for treating a bacterial infection caused by one or more bacterium selected from *Bacillus anthracis*, *Bacillus cereus*, *Burkholderia spp.*, *Brucella spp.*,  
5 *Francisella spp.*, *Yersina spp.*, *Mycoplasma spp.*, *Ureaplasma spp.*, *Chlamydia trachomatis* or *Chlamydia pneumoniae* in a subject in need thereof comprising administering an effective amount of (2*R*,4*S*,4*aS*)-11-fluoro-2,4-dimethyl-8-[(4*S*)-4-methyl-2-oxo-1,3-oxazolidin-3-yl]-1,2,4,4*a*-tetrahydro-2'*H*,6'*H*-spiro[1,4-oxazino[4,3-*a*][1,2]oxazolo[4,5-*g*]quinoline-5,5'-pyrimidine]-2',4',6'(1'*H*,3'*H*)-trione, or a pharmaceutically acceptable salt thereof, to the  
10 subject.
2. Use of (2*R*,4*S*,4*aS*)-11-fluoro-2,4-dimethyl-8-[(4*S*)-4-methyl-2-oxo-1,3-oxazolidin-3-yl]-1,2,4,4*a*-tetrahydro-2'*H*,6'*H*-spiro[1,4-oxazino[4,3-*a*][1,2]oxazolo[4,5-*g*]quinoline-5,5'-pyrimidine]-2',4',6'(1'*H*,3'*H*)-trione, or a pharmaceutically acceptable salt thereof, for treating  
15 a bacterial infection caused by one or more bacterium selected from *Bacillus anthracis*, *Bacillus cereus*, *Burkholderia spp.*, *Brucella spp.*, *Francisella spp.*, *Yersina spp.*, *Mycoplasma spp.*, *Ureaplasma spp.*, *Chlamydia trachomatis* or *Chlamydia pneumoniae*.
3. (2*R*,4*S*,4*aS*)-11-fluoro-2,4-dimethyl-8-[(4*S*)-4-methyl-2-oxo-1,3-oxazolidin-3-yl]-  
20 1,2,4,4*a*-tetrahydro-2'*H*,6'*H*-spiro[1,4-oxazino[4,3-*a*][1,2]oxazolo[4,5-*g*]quinoline-5,5'-pyrimidine]-2',4',6'(1'*H*,3'*H*)-trione, or a pharmaceutically acceptable salt thereof, for use in treating a bacterial infection caused by one or more bacterium selected from *Bacillus anthracis*, *Bacillus cereus*, *Burkholderia spp.*, *Brucella spp.*, *Francisella spp.*, *Yersina spp.*, *Mycoplasma spp.*, *Ureaplasma spp.*, *Chlamydia trachomatis* or *Chlamydia pneumoniae*.  
25
4. Use of (2*R*,4*S*,4*aS*)-11-fluoro-2,4-dimethyl-8-[(4*S*)-4-methyl-2-oxo-1,3-oxazolidin-3-yl]-1,2,4,4*a*-tetrahydro-2'*H*,6'*H*-spiro[1,4-oxazino[4,3-*a*][1,2]oxazolo[4,5-*g*]quinoline-5,5'-pyrimidine]-2',4',6'(1'*H*,3'*H*)-trione, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating a bacterial infection caused by one or more  
30 bacterium selected from *Bacillus anthracis*, *Bacillus cereus*, *Burkholderia spp.*, *Brucella spp.*, *Francisella spp.*, *Yersina spp.*, *Mycoplasma spp.*, *Ureaplasma spp.*, *Chlamydia trachomatis* or *Chlamydia pneumoniae*.
5. A pharmaceutical composition comprising (2*R*,4*S*,4*aS*)-11-fluoro-2,4-dimethyl-8-  
35 [(4*S*)-4-methyl-2-oxo-1,3-oxazolidin-3-yl]-1,2,4,4*a*-tetrahydro-2'*H*,6'*H*-spiro[1,4-oxazino[4,3-*a*][1,2]oxazolo[4,5-*g*]quinoline-5,5'-pyrimidine]-2',4',6'(1'*H*,3'*H*)-trione, or a pharmaceutically acceptable salt thereof, for treating a bacterial infection caused by one or more bacterium

selected from *Bacillus anthracis*, *Bacillus cereus*, *Burkholderia spp.*, *Brucella spp.*, *Francisella spp.*, *Yersina spp.*, *Mycoplasma spp.*, *Ureaplasma spp.*, *Chlamydia trachomatis* or *Chlamydia pneumoniae*.

- 5 6. The method of claim 1, wherein the subject is a human.
7. The method of claim 1, wherein the subject is suffering from more than one bacterial infection.
- 10 8. The method of claim 7, wherein the subject is suffering from a *Chlamydia trachomatis* infection and a *Neisseria gonorrhoeae* infection.
9. The method of claim 1, wherein the bacteria is resistant to one or more antibacterials other than (2*R*,4*S*,4*aS*)-11-fluoro-2,4-dimethyl-8-[(4*S*)-4-methyl-2-oxo-1,3-oxazolidin-3-yl]-1,2,4,4*a*-tetrahydro-2'*H*,6*H*-spiro[1,4-oxazino[4,3-*a*][1,2]oxazolo[4,5-*g*]quinoline-5,5'-pyrimidine]-2',4',6'(1'*H*,3'*H*)-trione.
- 15

INTERNATIONAL SEARCH REPORT

International application No  
PCT/IB2015/001585

A. CLASSIFICATION OF SUBJECT MATTER  
INV. A61K31/538 A61P31/04  
ADD.  
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED  
Minimum documentation searched (classification system followed by classification symbols)  
A61K  
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
EPO-Internal, WPI Data, BIOSIS, EMBASE, CHEM ABS Data, BEILSTEIN Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P	WO 2014/114929 A1 (ASTRAZENECA AB [SE]; ASTRAZENECA UK LTD [GB]) 31 July 2014 (2014-07-31) page 16; compound 5th page 34, line 31 - line 35 page 35, line 6 - line 9 page 38, line 27 page 148, line 1 - line 22; example 5 page 215 - page 216; table 12	1-7,9
X	WO 2010/043893 A1 (ASTRAZENECA AB [SE]; ASTRAZENECA UK LTD [GB]; BARVIAN KEVIN [US]; BASA) 22 April 2010 (2010-04-22) page 312; example 71 page 314; example 74(a) page 63, line 10 - line 12 page 63, line 15 - line 16 page 64, line 11 - line 13 ----- -/--	1-7,9

Further documents are listed in the continuation of Box C.

See patent family annex.

\* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier application or patent but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search  2 November 2015	Date of mailing of the international search report  09/11/2015
Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Authorized officer  Opravz, Petra

## INTERNATIONAL SEARCH REPORT

International application No  
PCT/IB2015/001585

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P	KOHLHOFF STEPHAN A ET AL: "In Vitro Activity of AZD0914, a Novel DNA Gyrase Inhibitor, against Chlamydia trachomatis and Chlamydia pneumoniae", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 58, no. 12, December 2014 (2014-12), pages 7595-7596, XP002749516, ISSN: 0066-4804(print) the whole document	1-9
X,P	----- Waites K B et al.: "In Vitro Antibacterial Activity of AZD0914 Against Human Mycoplasmas and Ureaplasmas", INTERNET  25 March 2015 (2015-03-25), XP002749517, Retrieved from the Internet: URL:http://aac.asm.org/content/early/2015/03/24/AAC.04945-14.full.pdf [retrieved on 2015-10-30] the whole document	1-7,9
X,P	----- Huband M D et al.: "In Vitro Antibacterial Activity of AZD0914 and Comparators against Mycoplasma, Ureaplasma, and Chlamydia", INTERNET  6 September 2014 (2014-09-06), XP002749518, Retrieved from the Internet: URL:http://www.icaaconline.com/php/icaac2014abstracts/data/papers/2014/F-265.htm [retrieved on 2015-10-30] abstract	1-7,9
X,P	----- Huband M D et al.: "In Vitro Antibacterial Activity of AZD0914: A New Spiropyrimidinetrione Bacterial DNA Gyrase Inhibitor against Potential Agents of Bioterrorism", INTERNET  6 September 2014 (2014-09-06), XP002749519, Retrieved from the Internet: URL:http://www.icaaconline.com/php/icaac2014abstracts/data/papers/2014/F-264.htm [retrieved on 2015-10-30] abstract -----	1-7,9

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No PCT/IB2015/001585
---

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2014114929 A1	31-07-2014	AU 2014208965 A1	30-07-2015
		CA 2897887 A1	31-07-2014
		IL 239860 A	31-08-2015
		KR 20150107875 A	23-09-2015
		SG 11201505462Y A	28-08-2015
		TW 201443063 A	16-11-2014
		US 2014206677 A1	24-07-2014
		US 2015203513 A1	23-07-2015
		UY 35274 A	31-07-2014
		WO 2014114929 A1	31-07-2014
-----			
WO 2010043893 A1	22-04-2010	AR 073862 A1	09-12-2010
		AU 2009305203 A1	22-04-2010
		CA 2736335 A1	22-04-2010
		CN 102245605 A	16-11-2011
		CN 104086565 A	08-10-2014
		CO 6382126 A2	15-02-2012
		CR 20110195 A	08-06-2011
		CU 20110083 A7	31-05-2013
		DO P2011000102 A	15-05-2011
		EA 201100613 A1	30-12-2011
		EC SP11010980 A	31-05-2011
		EP 2350077 A1	03-08-2011
		JP 5749169 B2	15-07-2015
		JP 2012505261 A	01-03-2012
		JP 2015178510 A	08-10-2015
		KR 20110090895 A	10-08-2011
		TW 201020258 A	01-06-2010
		US 2011245224 A1	06-10-2011
		UY 32174 A	31-05-2010
		WO 2010043893 A1	22-04-2010
-----			